Clinical commissioning statement: plerixafor use in patients with transfusion-dependent beta-thalassaemia who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above)

Document first published:
Page updated:
Topic:
Publication type:

Clinical commissioning statement for plerixafor for use in patients with transfusion-dependent beta-thalassaemia who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above).

Document

Clinical commissioning statement: plerixafor use in patients with transfusion-dependent beta-thalassaemia who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above)

Clinical commissioning statement: plerixafor use in patients with transfusion-dependent beta-thalassaemia who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above)

  • PDF
  • 190 KB
  • 8 pages

Summary

Published 19 August 2024.

Document

Equality and health inequalities impact assessment: plerixafor use in patients with transfusion-dependent beta-thalassaemia who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above)

Equality and health inequalities impact assessment: plerixafor use in patients with transfusion-dependent beta-thalassaemia who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above)

  • PDF
  • 190 KB
  • 9 pages

Summary

Published 19 August 2024.